P5091 (P005091)
Catalog No.S7132
Molecular Weight(MW): 348.22
P5091(P005091) is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM and the closely related USP47.
4 Customer Reviews
-
(e) MM.1S cells were treated with RRx-001 (1.25 μM), P5091 (3 μM) or RRx-001 plus P5091 for 12 h; protein extracts were analyzed for total DNMT activity using the EpiQuik DNMT activity kit (mean±s.d.; P<0.001; n=3). (f) MM.1S cells were treated with RRx-001 (1.25 μM), P5091 (3 μM) or RRx-001 plus P5091 for 12 h; protein lysates were then subjected to immunoblot analysis using antibodies specific against p21, HDM2, p53 or GAPDH.
Leukemia, 2016, 30(11):2187-2197.. P5091 (P005091) purchased from Selleck.
-
MM.1S cells were treated with RRx-001 (1.25 µM), P5091 (3 µM), or RRx-001 plus P5091 for 12h; protein extracts were analyzed for total DNMT activity using EpiQuik DNMT activity kit (mean ± SD; p < 0.001; n=3).
Leukemia, 2016, 30(11):2187-2197. P5091 (P005091) purchased from Selleck.
-
The USP7 inhibitor P5091 suppresses ovarian cancer cell growth in vitro. Cultured ovarian cancer cells were treated with various concentrations of P5091 as indicated and cell proliferation was measured with MTT assays. A, B, C, and D represent SKOV3, HeyA8, OVCAR-8, and T80 cells, respectively. All error bars represent standard error of the mean (n = 3, * represents p<0.05). E and F, HeyA8 and OVCAR-8 cells were treated with 50 µM of P5091 for 12 and 24 hours before examination under a phase contrast microscope. Control cells were treated with DMSO. Representative micrographs are shown to illustrate morphology changes (scale bar = 100 µm).
Cell Physiol Biochem, 2017, 43(5):1755-1766. P5091 (P005091) purchased from Selleck.
-
P5091 attenuates the TopFlash activity and the expression of Wnt target genes in colorectal cancer cells. (A) P5091 repressed the activity of Wnt signaling in HEK293W cells. HEK293W cells seeded in 96-well plates were incubated with indicated concentrations of P5091 for 24 h. The Luciferase activity was then measured and normalized to the activity of the Renilla (Relative Luciferase Activity, RLA). (B) P5091 attenuated the activation of Wnt signaling initiated by Wnt1 in HEK293 cells. HEK293 cells in 96-well plates were transiently transfected with SuperTopflash and Renilla constructs, with or without Wnt1. 3 h after transfection, cells were treated with indicated doses of P5091 for 24 h, and the luciferase activity were measured and normalized to the activity of Renilla. (C) HCT116 cells, SW480 cells and Caco-2 cells in 96-well plates were transiently cotransfected with plasmids of SuperTopflash and Renilla. After Incubation for 3 h, cells were treated with the indicated concentrations of P5091 for 24 h, after which cells were lysed and underwent dual luciferase reporter assay. The values represented the mean ± SD (n = 3). The significance was determined by student’s t test (ap < 0.05 and bp ≤ 0.01 vs. control). (D) Western blot of Wnt signaling downstream target protein in HCT116 cells, SW480 cells and Caco-2 cells treated with the indicated doses of P5091, actin were used as the loading control. (E) Quantification of indicated protein levels in (D) by NIH ImageJ software. The values represented the mean ± SD (n = 3). The significance was determined by student’s t test (ap < 0.05, bp ≤ 0.01 and cp ≤ 0.001 vs. control). RLA is the abbreviation of relative luciferase activity.
Biochem Pharmacol, 2017, 131:29-39. P5091 (P005091) purchased from Selleck.
Purity & Quality Control
Choose Selective DUB Inhibitors
Biological Activity
| Description | P5091(P005091) is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM and the closely related USP47. | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
|||||||||||||||||||||||
| In vitro |
P5091 is a trisubstituted thiophene with dichlorophenylthio, nitro, and acetyl substituents mediating anti-USP7 activity. P5091 exhibits potent, specific, and selective deubiquitylating activity against USP7. In contrast, P5091 does not inhibit other DUBs or other families of cysteine proteases tested (EC50 > 100 mM). P5091 inhibits the labeling of USP7 with HA-UbVME in a concentration-dependent manner. USP7-mediated cleavage of high molecular weight polyubiquitin chains is inhibited in a dose-dependent manner by P5091. Moreover, P5091 inhibits USP7- but not USP2- or USP8-mediated cleavage of poly K48-linked ubiquitin chains. USP7 inhibition by P5091 induces HDM2 polyubiquitylation and accelerates degradation of HDM2. P5091 inhibits USP7 deubiquitylating activity, without blocking proteasome activity in MM Cells. P5091 inhibits growth in MM cells and overcomes bortezomib-resistance. P5091 induces a dose-dependent decrease in viability of various MM cell lines, including those that are resistant to conventional therapies dexamethasone (Dex) (MM.1R), doxorubicin (Dox-40), or melphalan (LR5) (IC50 range 6–14 μM). P5091 overcomes bone marrow stromal cell-induced growth of MM Cells. P5091 decreased HDM2 and HDMX, as well as upregulated p53 and p21 levels. Overall, P5091-induced cytotoxicity is mediated in part via HDM2-p21 signaling axis and although p53 is upregulated in response to P5091 treatment, the cytotoxic activity of P5091 is not dependent on p53. [1] |
|||||||||||||||||||||||
| Cell Data |
|
|||||||||||||||||||||||
| Assay |
|
|||||||||||||||||||||||
| In vivo | In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival. Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity. [1] |
Protocol
| Animal Research: |
- Collapse
|
|---|
Solubility (25°C)
| In vitro | DMSO | 28 mg/mL (80.4 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | Insoluble | |
| In vivo | Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 400+ddH2O For best results, use promptly after mixing. |
5mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 348.22 |
|---|---|
| Formula | C12H7Cl2NO3S2 |
| CAS No. | 882257-11-6 |
| Storage | powder |
| in solvent | |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
